Health Affairs, 28, no. 5 (2009): w794-w808
(Published online 21 July 2009)
doi: 10.1377/hlthaff.28.5.w794
© 2009 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Technical Appendices
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Google Scholar
* Articles by Meltzer, D. O.
* Articles by Meltzer, H. Y.
PubMed
* PubMed Citation
* Articles by Meltzer, D. O.
* Articles by Meltzer, H. Y.
Related Collections
* Insurance Coverage
* Legal/Regulatory Issues
* Managed Care - Mental Health
* Mental Health/Substance Abuse
* Research And Technology
* Health Spending
* Consumer Issues
* Evidence-Based Medicine
*Related Articles

Web Exclusives

Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?

David O. Meltzer, Anirban Basu and Herbert Y. Meltzer

Second-generation antipsychotics have attracted practitioners’ and policy-makers’ attention, because of concerns over their health effects and costs. Comparative effectiveness data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)—a high-profile National Institutes of Health (NIH)–funded study—have been used to argue for restricting coverage for these costly drugs. But concerns about the design of CATIE and its associated cost-effectiveness analysis and uncertainty about the precision of these findings raise questions about this interpretation. Our work suggests that additional research to increase the precision of comparisons of the effectiveness of antipsychotics would be well worth the cost.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?

Related Articles

  • Stephen Crystal, Mark Olfson, Cecilia Huang, Harold Pincus, and Tobias Gerhard
    Broadened Use Of Atypical Antipsychotics: Safety, Effectiveness, And Policy Challenges
    Health Affairs, September/October 2009; 28(5): w770-w781.
    [Abstract] [Full Text] [Figures Only] [PDF] [Appendices][TOC]
     
  • Robert A. Rosenheck and Michael J. Sernyak
    Developing A Policy For Second-Generation Antipsychotic Drugs
    Health Affairs, September/October 2009; 28(5): w782-w793.
    [Abstract] [Full Text] [PDF]